STAT+: The inside story of how Lykos’ MDMA research went awry
STAT
JUNE 9, 2024
At a heated advisory committee meeting convened by the Food and Drug Administration last week, regulators repeatedly expressed frustration that Lykos, a company seeking approval of MDMA-assisted therapy to treat PTSD , failed to follow instructions and track positive feelings such as “euphoria” that could be used to inform understanding of the drug’s addiction potential.
Let's personalize your content